Safety and Pharmacokinetics of GH002 in Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

A Phase 1 Clinical Trial to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous GH002 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05753956
• Other study ID #: GH002-HV-105
• Secondary ID: 2022-002620-13
• Status: Completed
• Phase: Phase 1
• Start date: December 22, 2022
• Est. completion date: November 29, 2023

Study information

• Verified date: January 2024
• Source: GH Research Ireland Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are to investigate the safety and serum pharmacokinetics of 5-MeO-DMT in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, injected doses of GH002 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH002. As secondary objectives, the PK/ pharmacodynamic relationship, PD profile of GH002 as evaluated by its psychoactive effects and impact on cognitive performance, and the serum PK of the metabolite bufotenine are also assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: November 29, 2023
• Est. primary completion date: November 29, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Has a body mass index (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) at Screening.

• Is deemed in good physical health by the investigator.

• Is in good mental health in the opinion of the investigator and clinical psychologist

Exclusion Criteria:

• Has known allergies or hypersensitivity or any other contra-indication to 5-MeO-DMT.

• Has received any investigational medication, including investigational vaccines, within the 6 weeks prior to baseline

• Has a current or past clinically significant condition, which renders the subject unsuitable for the trial according to the Investigator's judgement.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• 5 Methoxy N,N Dimethyltryptamine
GH002 administered via i.v. bolus injection(s)
• Placebo
GH002 placebo administered via i.v. bolus injection

Locations

Country	Name	City	State
Netherlands	GH Research Clinical Trial Site	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
GH Research Ireland Limited

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability: incidence of treatment emergent adverse events	Adverse events reported in the study and coded by MedDRA.	Up to 7 days
Primary	Safety and tolerability: local tolerance (injection site reactions)	Local infusion site findings will be assessed as none, mild, moderate and severe for the following signs and symptoms of the applicable site: dryness, redness, swelling, pain, tenderness, and itching and other.	Up to discharge on dosing day
Primary	Safety and tolerability: Clinically significant changes from baseline in ECG, vital signs and safety laboratory assessments	Clinically significant changes in ECG include any significant change in rate or rhythm as determined by the principal investigator	Up to 7 days
Primary	Safety and tolerability: Assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0	The Modified Observer's Assessment of Alertness and Sedation scale (MOAA/S) will be completed before and after GH002 dosing. Scored from 0 (deep sedation) to 5 (alert)	Up to discharge on dosing day
Primary	Safety and tolerability: Change from baseline in Clinician Administered Dissociative States Scale (CADSS)	The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76	Up to 7 days
Primary	Safety and tolerability: Assessment of subject-discharge readiness at discharge on Day 0	Assessment of Discharge Readiness on the administration day by the Principal Investigator, using the Clinical Assessment of Discharge Readiness (CADR).	Up to discharge on dosing day
Primary	Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization based on the Columbia Classification Algorithm of Suicide Assessment (C-CASA).	A detailed questionnaire assessing both suicidal behaviour and suicidal ideation.	Up to 7 days
Primary	Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).	A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126.	Up to 7 days
Primary	The pharmacokinetic (PK) parameters derived from laboratory assay results of the systemic levels of 5-MeO-DMT	For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH002 to determine 5-MeO-DMT serum concentrations.	Up to 6 hours
Secondary	Pharmacodynamic assessment: The dose-related psychoactive effects of GH002 as evaluated by a Visual Analogue Scale	The Peak Experience Scale (PES) is a Visual Analogue Scale scored from 0-100	Up to 1 hour after dosing
Secondary	Pharmacodynamic assessment: Challenging Experiences Questionnaire (CEQ)	Completed by the subject after GH002 administration and assesses seven factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) all scored from 0 to 5.	Up to 1 hour after dosing
Secondary	Pharmacodynamic assessment: 30-Question Mystical Experience Questionnaire (MEQ30)	The MEQ30 is a validated procedure for assessing the extent of the psychoactive effects experienced by a subject. The validated MEQ30 uses thirty assessment questions across four areas of experience, all scored from 0 to 5.	Up to 1 hour after dosing
Secondary	Pharmacodynamic assessment: Duration of the psychoactive effects (PsE)	The duration of the experience, defined as time in minutes from drug administration to time when the subject reports that any psychoactive symptoms have subsided will be recorded.	Up to 1 hour after dosing
Secondary	PK/PD relationship(s) of 5-MeO-DMT	In particular the correlation between Cmax and AUC with PES score and duration of PsE as scored by the investigator will be described	Up to 1 hour after dosing
Secondary	Cognitive Function: Change from baseline in Rapid visual information processing (RVP) test	A computerized test assessing the reaction time in response to a visual stimulus.	Up to 7 days
Secondary	Cognitive Function: Change from baseline in Verbal recognition memory (VRM) test	The VRM test is based on successive auditory presentations of 18-word lists followed by attempted recall.	Up to 7 days
Secondary	Cognitive Function: Change from baseline in Spatial Working Memory (SWM) task	The SWM test requires retention and manipulation of visuospatial information. This test has notable executive function demands, and measures strategy use as well as errors. In this task the subject has to search for tokens hidden in boxes on screen. The subject must touch a box to open the box to reveal either a yellow token or an empty box. Once the subject has found a yellow token, they must touch the outline of the right-hand side of the screen to 'store' it. The subject must then continue searching through the boxes until all of the tokens have been found. The test takes about 4 minutes to complete	Up to 7 days
Secondary	Cognitive Function: Change from baseline in Digit Symbol Substitution Task (DSST)	The DSST is a global measure of cognitive ability, requiring the engagement of multiple cognitive domains in order to complete effectively. A computerized test with the task is to match digits with symbols from encoding list. The number of digits correctly encoded within 90 seconds is the performance measure.	Up to 7 days
Secondary	The pharmacokinetic (PK) parameters derived from laboratory assay results of the systemic levels of bufotenine	For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH002 to determine bufotenine serum concentrations.	Up to 6 hours